Welcome to our dedicated page for Brainstorm Cell Therapeutics I news (Ticker: BCLI), a resource for investors and traders seeking the latest updates and insights on Brainstorm Cell Therapeutics I stock.
BrainStorm Cell Therapeutics Inc. develops autologous adult stem cell therapeutics for neurodegenerative diseases, with news centered on its investigational NurOwn® platform for amyotrophic lateral sclerosis. NurOwn uses bone marrow-derived mesenchymal stem cells expanded and differentiated ex vivo into neurotrophic factor-secreting MSC-NTF cells designed to deliver neurotrophic factors and immunomodulatory cytokines.
Company updates commonly cover financial results, private placements and working-capital actions, regulatory engagement with the FDA, manufacturing readiness and clinical development activities tied to the Phase 3b ENDURANCE study. Corporate updates also address the completed transition of BCLI common stock from Nasdaq listing to OTCQB quotation.
BrainStorm Cell Therapeutics announced a lease with Tel Aviv Sourasky Medical Center to produce NurOwn® in new cleanrooms, enhancing manufacturing capacity for ALS treatment in Israel and the EU. This collaboration aims to ensure rapid production post-regulatory approval, supporting ongoing clinical demands. The cleanroom facility complies with cGMP standards, indicating a significant step toward scaling up operations. With full enrollment in a Phase 3 ALS trial and recent FDA clearance for a Phase 2 MS trial, BrainStorm is positioned to advance its therapeutic pipeline significantly.
Summary not available.